MaxCyte, Inc. (NASDAQ:MXCT) Receives Consensus Rating of “Hold” from Analysts

Shares of MaxCyte, Inc. (NASDAQ:MXCT) have received a consensus rating of “Hold” from the five analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $7.00.

Several equities analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of MaxCyte in a research note on Monday, December 29th. Wall Street Zen upgraded shares of MaxCyte from a “sell” rating to a “hold” rating in a report on Saturday.

Hedge Funds Weigh In On MaxCyte

Hedge funds have recently made changes to their positions in the company. Farther Finance Advisors LLC grew its position in MaxCyte by 7,935.4% during the 2nd quarter. Farther Finance Advisors LLC now owns 11,812 shares of the company’s stock worth $26,000 after purchasing an additional 11,665 shares during the last quarter. Prudential Financial Inc. purchased a new stake in shares of MaxCyte in the second quarter valued at $26,000. CWM LLC grew its stake in MaxCyte by 92.7% in the 2nd quarter. CWM LLC now owns 12,132 shares of the company’s stock worth $26,000 after acquiring an additional 5,836 shares during the period. May Hill Capital LLC purchased a new stake in MaxCyte in the 2nd quarter valued at about $27,000. Finally, State of Wyoming acquired a new stake in shares of MaxCyte during the 2nd quarter worth $38,000. Hedge funds and other institutional investors own 68.81% of the company’s stock.

MaxCyte Stock Down 2.1%

MaxCyte stock opened at $0.79 on Thursday. MaxCyte has a 52-week low of $0.75 and a 52-week high of $4.42. The firm has a market cap of $84.42 million, a PE ratio of -1.80 and a beta of 1.21. The company’s 50 day moving average is $1.35 and its two-hundred day moving average is $1.51.

MaxCyte (NASDAQ:MXCT) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.01). The company had revenue of $6.41 million for the quarter, compared to analysts’ expectations of $8.37 million. MaxCyte had a negative return on equity of 23.50% and a negative net margin of 132.57%. On average, equities research analysts anticipate that MaxCyte will post -0.42 earnings per share for the current fiscal year.

About MaxCyte

MaxCyte, Inc (NASDAQ: MXCT) is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company’s instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.